MetaSight Diagnostics News
2 articles
growth-positive
MetaSight Diagnostics Raises $8M in Over-Subscribed Series A Funding Round
MetaSight Diagnostics, a health technology company based in Israel, has successfully closed an $8 million Series A financing round. The investment, led by new investors including aMoon Growth II Fund, Saban Ventures, ARC Ventures, and Alumni Ventures, will be used to advance MetaSights diagnostic programs into FDA trials and expand its product portfolio. The company, founded in 2021, specializes in multi-omics screening and diagnostic products for diseases such as colorectal cancer and metabolic dysfunction-associated steatohepatitis. MetaSight plans to use the funds to further develop its pipeline and engage in strategic partnerships, with the aim of making its tests available in selected markets by 2025.
InvestmentExpandPartners
growth-positive
פרופ' תומר שלומי הפעיל את המכונה קצת אחרת – וגילה קיצור דרך לבדיקות דם חדשות
MetaSight, a startup founded by Professor Tomer Shlomi from the Technion, has developed an algorithm that accelerates the analysis of blood samples using mass spectrometry. This innovation aims to make medical diagnostics more affordable and accessible to the general population. The company has successfully raised approximately $20 million in funding. Mass spectrometers, traditionally expensive and complex devices used in chemistry and biology labs, analyze the composition of blood samples, identifying proteins, fatty acids, and other molecules. Typically, each test takes about half an hour and costs several hundred dollars. MetaSights advancement could significantly reduce these costs and timeframes, potentially transforming the medical diagnostics industry.
Investment
